{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative directly modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_16464", "batch_size": 36, "batch_pos": 33, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 2, "answer": "no", "rationale": "The segment describes a deal using neutral language, lacking Q2 cues.", "method": "llm_batch", "batch_id": "batch_2_19432", "batch_size": 196, "batch_pos": 193, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 3, "answer": "no", "rationale": "The segment contains scale ('up to 665,000 doses', '40 million vaccines') but discusses procurement/trade ('deal secures', 'vaccine manufacturer'), triggering the financial/trade guard.", "method": "llm_batch", "batch_id": "batch_3_15728", "batch_size": 108, "batch_pos": 105, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 4, "answer": "no", "rationale": "No question is present in the segment.", "method": "llm_batch", "batch_id": "batch_4_12664", "batch_size": 102, "batch_pos": 99, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 5, "answer": "no", "rationale": "Reports details of a deal, no explicit calming cues.", "method": "llm_batch", "batch_id": "batch_5_20156", "batch_size": 96, "batch_pos": 93, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 6, "answer": "no", "rationale": "Mentions dose numbers but lacks a minimiser used with scale contrast.", "method": "llm_batch", "batch_id": "batch_6_13300", "batch_size": 25, "batch_pos": 22, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 7, "answer": "no", "rationale": "Segment does not contain a bare negation.", "method": "llm_batch", "batch_id": "batch_7_11420", "batch_size": 8, "batch_pos": 5, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 8, "answer": "yes", "rationale": "Describes the terms of a deal securing resources (preparedness): 'secures up to 665,000 doses', 'includes an option for a further 40 million vaccines'.", "method": "llm_batch", "batch_id": "batch_8_21452", "batch_size": 105, "batch_pos": 102, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
